Relevant bibliographies by topics / Human biotherapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters

Academic literature on the topic 'Human biotherapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Human biotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Human biotherapy"

1

Volgareva, G. M. "PAPILLOMAVIRAL CARCINOGENESIS. SIGNIFICANT ACHIEVEMENTS AND SPECIFIC CHALLENGES. PART 3. THREE LEVELS OF CERVICAL CANCER PREVENTION AND TREATMENT." Russian Journal of Biotherapy 19, no. 3 (2020): 6–11. http://dx.doi.org/10.17650/1726-9784-2020-19-3-6-11.

Full text
Abstract:
Efficient prophylactic vaccines have been developed to prevent cervical cancer, a frequent female oncological disease caused by carcinogenic human papillomaviruses. World Health Organization worked out the program for prophylaxis of cervical cancer and control of the disease. It includes preventive adolescent vaccinations, screening of precancerous cervical lesions in women as well as cervical cancer treatment if originated. Cervical cancer diagnostics is being improved, development of therapeutic human papillomaviruses vaccines is in progress. The review deals with major achievements and certain challenges in the field of cervical cancer prevention.Part I see: Volgareva G.M. Papillomaviral carcinogenesis. Major achievements and certain challenges. Part I. General notions of papillomaviruses. Human papillomavirusesassociated cancers. Russian Journal of Biotherapy 2020;19(1):6–12.Part 2 see: Volgareva G.M. Papillomaviral carcinogenesis. Major achievements and certain challenges. Part 2. HPV-associated cancers in Russia. Preventive HPV vaccines. Russian Journal of Biotherapy 2020;19(2):31–8.
APA, Harvard, Vancouver, ISO, and other styles
2

Gopalakrishnan, Gopakumar, Sinda Lepetre, Andrei Maksimenko, Simona Mura, Didier Desmaële, and Patrick Couvreur. "Lipid‐Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer." Advanced Healthcare Materials 4, no. 7 (2015): 1015–22. http://dx.doi.org/10.1002/adhm.201400816.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Song, Chaoying, Jiali Zhang, Zongyao Zhao, et al. "DLEU1: A Functional Long Noncoding RNA in Tumorigenesis." Current Pharmaceutical Design 26, no. 15 (2020): 1742–48. http://dx.doi.org/10.2174/1381612826666200122145305.

Full text
Abstract:
Background: LncRNA DLEU1 participates in various biological processes, playing an indispensable role in the pathophysiology of human diseases, especially in tumorigenesis and other processes. Besides, it may represent a promising target for biotherapy in numerous tumors. The aim of this review was to reveal the pathophysiological functions and mechanisms of lncRNA DLEU1 in different types of cancer. Methods: LncRNA DLEU1 participates in various biological processes, playing an indispensable role in the pathophysiology of human diseases, especially in tumorigenesis and other processes. Besides, it may represent a promising target for biotherapy in numerous tumors. The aim of this review was to reveal the pathophysiological functions and mechanisms of lncRNA DLEU1 in different types of cancer. Results: DLEU1 is a novel cancer-associated lncRNA that has been proved to be abnormally elevated in various malignancies, containing osteosarcoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, bladder cancer, cervical cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer, oral squamous cell carcinoma, endometrial cancer, gastric cancer, Burkitt lymphoma and ovarian carcinoma. Besides, lncRNA LDEU1 has been demonstrated involving in the procession of proliferation, migration, invasion and inhibition of apoptosis of cancer cells. Conclusion: Long non-coding RNA DLEU1 is likely to represent an available biomarker or a potential therapeutic target in multiple tumors.
APA, Harvard, Vancouver, ISO, and other styles
4

Naji, Abderrahim, Nathalie Rouas-Freiss, Antoine Durrbach, Edgardo D. Carosella, Luc Sensébé, and Frédéric Deschaseaux. "Concise review: Combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy." STEM CELLS 31, no. 11 (2013): 2296–303. http://dx.doi.org/10.1002/stem.1494.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Davis, Harold W., Subrahmanya D. Vallabhapurapu, Zhengtao Chu, et al. "Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles." Cells 9, no. 9 (2020): 1960. http://dx.doi.org/10.3390/cells9091960.

Full text
Abstract:
Glioblastoma multiforme (GBM), a common type of brain cancer, has a very poor prognosis. In general, viable GBM cells exhibit elevated phosphatidylserine (PS) on their membrane surface compared to healthy cells. We have developed a drug, saposin C-dioleoylphosphatidylserine (SapC-DOPS), that selectively targets cancer cells by honing in on this surface PS. To examine whether SapC-DOPS, a stable, blood–brain barrier-penetrable nanovesicle, could be an effective delivery system for precise targeted therapy of radiation, we iodinated several carbocyanine-based fluorescent reporters with either stable iodine (127I) or radioactive isotopes (125I and 131I). While all of the compounds, when incorporated into the SapC-DOPS delivery system, were taken up by human GBM cell lines, we chose the two that best accumulated in the cells (DiI (22,3) and DiD (16,16)). Pharmacokinetics were conducted with 125I-labeled compounds and indicated that DiI (22,3)-SapC-DOPS had a time to peak in the blood of 0.66 h and an elimination half-life of 8.4 h. These values were 4 h and 11.5 h, respectively, for DiD (16,16)-SapC-DOPS. Adult nude mice with GBM cells implanted in their brains were treated with 131I-DID (16,16)-SapC-DOPS. Mice receiving the radionuclide survived nearly 50% longer than the control groups. These data suggest a potential novel, personalized treatment for a devastating brain disease.
APA, Harvard, Vancouver, ISO, and other styles
6

Chakrabarty, Paramita, Andrew Li, Thomas B. Ladd, et al. "TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease." Journal of Experimental Medicine 215, no. 9 (2018): 2247–64. http://dx.doi.org/10.1084/jem.20180484.

Full text
Abstract:
There is considerable interest in harnessing innate immunity to treat Alzheimer’s disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG4 Fc (sTLR5Fc) results in robust attenuation of amyloid β (Aβ) accumulation in a mouse model of Alzheimer-type Aβ pathology. sTLR5Fc binds to oligomeric and fibrillar Aβ with high affinity, forms complexes with Aβ, and blocks Aβ toxicity. Oligomeric and fibrillar Aβ modulates flagellin-mediated activation of human TLR5 but does not, by itself, activate TLR5 signaling. Genetic analysis shows that rare protein coding variants in human TLR5 may be associated with a reduced risk of AD. Further, transcriptome analysis shows altered TLR gene expression in human AD. Collectively, our data suggest that TLR5 decoy receptor–based biologics represent a novel and safe Aβ-selective class of biotherapy in AD.
APA, Harvard, Vancouver, ISO, and other styles
7

Kim, Yong Chan, Ravikiran Bhairavabhotla, Jeongheon Yoon, et al. "Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion." Blood 119, no. 12 (2012): 2810–18. http://dx.doi.org/10.1182/blood-2011-09-377895.

Full text
Abstract:
Abstract Foxp3+ regulatory T cells (Tregs) maintain self-tolerance and adoptive therapy, and using Foxp3+ Tregs has been proposed as treatment for autoimmune diseases. The clinical use of Tregs will require large numbers of cells and methods for in vitro expansion of Tregs are being developed. Foxp3+ Tregs can be divided into 2 subpopulations based on expression of the transcription factor, Helios. Foxp3+Helios+ Tregs (70%) are thymic-derived, whereas Foxp3+Helios− Tregs (30%) are induced in the periphery. Foxp3+Helios+ Tregs differ from Foxp3+Helios− Tregs in terms of epigenetic changes at the Foxp3 locus, their capacity to produce effector cytokines, and their stability of Foxp3 expression on days to weeks of expansion in vitro. Addition of a 25 mer DNA oligonucleotide of random composition for a short period during the expansion of Foxp3+ Tregs in vitro results in prolonged stabilization of the Foxp3+Helios+ subpopulation and yields an optimal population for use in cellular biotherapy.
APA, Harvard, Vancouver, ISO, and other styles
8

Li, Guanbao, Pinquan Li, Qiuan Chen, Hnin Ei Thu, and Zahid Hussain. "Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies." Current Drug Delivery 16, no. 2 (2018): 94–110. http://dx.doi.org/10.2174/1567201815666181024142354.

Full text
Abstract:
Background:Owing to their great promise in the spinal surgeries, bone graft substitutes have been widely investigated for their safety and clinical potential. By the current advances in the spinal surgery, an understanding of the precise biological mechanism of each bone graft substitute is mandatory for upholding the induction of solid spinal fusion.Objective:The aim of the present review is to critically discuss various surgical implications and level of evidence of most commonly employed bone graft substitutes for spinal fusion.Method:Data was collected via electronic search using “PubMed”, “SciFinder”, “ScienceDirect”, “Google Scholar”, “Web of Science” and a library search for articles published in peer-reviewed journals, conferences, and e-books.Results:Despite having exceptional inherent osteogenic, osteoinductive, and osteoconductive features, clinical acceptability of autografts (patient’s own bone) is limited due to several perioperative and postoperative complications i.e., donor-site morbidities and limited graft supply. Alternatively, allografts (bone harvested from cadaver) have shown great promise in achieving acceptable bone fusion rate while alleviating the donor-site morbidities associated with implantation of autografts. As an adjuvant to allograft, demineralized bone matrix (DBM) has shown remarkable efficacy of bone fusion, when employed as graft extender or graft enhancer. Recent advances in recombinant technologies have made it possible to implant growth and differentiation factors (bone morphogenetic proteins) for spinal fusion.Selection of a particular bone grafting biotherapy can be rationalized based on the level of spine fusion, clinical experience and preference of orthopaedic surgeon, and prevalence of donor-site morbidities.
APA, Harvard, Vancouver, ISO, and other styles
9

Mazier, Wilfrid, Katy Le Corf, Ccori Martinez, et al. "A New Strain of Christensenella minuta as a Potential Biotherapy for Obesity and Associated Metabolic Diseases." Cells 10, no. 4 (2021): 823. http://dx.doi.org/10.3390/cells10040823.

Full text
Abstract:
Obesity is associated with gut microbiota dysbiosis, characterized by a high Firmicutes/Bacteroidetes ratio. Gut-dwelling bacteria of the Christensenellaceae family have been proposed to act as keystones of the human gut ecosystem and to prevent adipogenesis. The objectives of the present study were to demonstrate the antiobesity potential of a new strain of Christensenella minuta in preclinical models and explore related mechanisms of action. The antiobesity potential of C. minuta DSM33407 was assessed in a diet-induced obesity mouse model. Changes in hepatic lipid metabolism were explored using targeted transcriptomics. Effects on gut microbiota were further assessed in a humanized Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model inoculated with obese fecal samples. Shotgun metagenomics was applied to study microbial community structures in both models. C. minuta DSM33407 protected from diet-induced obesity and regulated associated metabolic markers such as glycemia and leptin. It also regulated hepatic lipid metabolism through a strong inhibition of de novo lipogenesis and maintained gut epithelial integrity. In the humanized SHIME® model, these effects were associated with modulations of the intestinal microbiota characterized by a decreased Firmicutes/Bacteroidetes ratio. These data indicate that C. minuta DSM33407 is a convincing therapeutic candidate for the management of obesity and associated metabolic disorders.
APA, Harvard, Vancouver, ISO, and other styles
10

Giuliani, Massimo, Noufissa Oudrhiri, Zaeem M. Noman, et al. "Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery." Blood 118, no. 12 (2011): 3254–62. http://dx.doi.org/10.1182/blood-2010-12-325324.

Full text
Abstract:
Abstract A major issue in immunosuppressive biotherapy is the use of mesenchymal stem cells (MSCs) that harbor regulatory capacity. However, currently used bone marrow-derived MSCs (BM-MSCs) are short-lived and cannot assure long lasting immunoregulatory function both in vitro and in vivo. Consequently, we have generated MSCs from human induced pluripotent stem (IPS-MSCs) cells that share similar properties with embryonic stem cells (ES-MSCs). Herein, we compared the immunoregulatory properties of ES/IPS-MSCs with those of BM-MSCs and showed, for the first time, that IPS-derived MSCs display remarkable inhibition of NK-cell proliferation and cytolytic function in a similar way to ES-MSCs. Both MSCs disrupt NK-cell cytolytic machinery in the same fashion that BM-MSCs, by down-regulating the expression of different activation markers and ERK1/2 signaling, leading to an impairment to form immunologic synapses with target cells and, therefore, secretion of cytotoxic granules. In addition, they are more resistant than adult BM-MSCs to preactivated NK cells. IPS-MSCs could represent an attractive alternative source of immunoregulatory cells, and their capacity to impair NK-cell cytotoxicity constitutes a complex mechanism to prevent allograft rejection.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Human biotherapy"

1

Britland, Stephen T., Annie G. Smith, Wayne Finter, et al. "Recombinant Lucilia Sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo." 2011. http://hdl.handle.net/10454/7438.

Full text
Abstract:
no<br>Larval biotherapy is a debridement tool used in wound management. The mechanism of action involves degradation of eschar by serine proteases including chymotrypsin within the alimentary fluids of first instar Lucilia sericata. With the rationale of obviating some limitations of biotherapy, including cost, complexity of use, and patient reticence, the present study describes a mobile hydrogel formulation containing freeze-dried recombinant L. sericata chymotrypsin designed for topical application. Neither freeze-drying nor formulation into the hydrogel significantly attenuated the measured activity of released enzyme compared to fresh-frozen enzyme in aqueous solution. Gel electrophoresis confirmed qualitatively that the chymotrypsin/hydrogel formulation both with and without supplementary urea at 10% w/v degraded human chronic wound eschar ex vivo. Mindful that the hallmark of intractability of chronic wounds is aberrant biochemistry, the pH activity profile for the enzyme/hydrogel formulation was compared with exudate pH in chronic wounds of mixed aetiology in a cohort of 48 hospital in-patients. Five patients' wounds were acidic, however, the remainder were predominantly alkaline and coincided with the pH optimum for the insect enzyme. Thus, a recombinant L. sericata chymotrypsin and hydrogel formulation could represent a pragmatic alternative to larval therapy for the management of chronic wounds.
APA, Harvard, Vancouver, ISO, and other styles
2

Pinder, Shaun. "Detecting Changes in the Gut Microbiome following Human Biotherapy via Pyrosequencing of the 16S rRNA Gene." Thesis, 2013. http://hdl.handle.net/10214/6578.

Full text
Abstract:
Human biotherapy (HBT) or fecal transplants have been shown to be an effective treatment for patients with recurrent Clostridium difficile infection (CDI). This study examines the microbial populations present in CDI patients pre- and post-HBT by extracting bacterial DNA from stool samples and performing pyrosequencing of the 16S rRNA gene. We then compared these microbial populations to those of the donors. We examined 19 pairs of patient samples, of which 14 were clinically cured of CDI, and 5 patients were failures. The successful treatment of CDI was associated with an increase in diversity and richness of the patient's fecal microbiome. The majority of those cured showed an increase in the proportion of Firmicutes and decrease in the proportion of Proteobacteria, although varying antibiotic exposure and innate variability between patients was observed.<br>MSc thesis<br>NSERC, CIHR, St. Joseph's Healthcare Hamilton
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Human biotherapy"

1

Wroblewski, Joanne M., and John R. Yannelli. "Recent advances in the cellular immunotherapy of human cancer." In Principles of Cancer Biotherapy. Springer Netherlands, 2003. http://dx.doi.org/10.1007/978-94-017-2757-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Guest, Claire. "Canine Olfactory Detection of Human Disease." In Biotherapy - History, Principles and Practice. Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-6585-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yannelli, John R. "Update on the Laboratory Aspects of the Cellular Immunotherapy of Human Cancer." In Principles of Cancer Biotherapy. Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-009-0029-5_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Human biotherapy' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography